Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GTAEXS617 · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1: Dose Escalation Monotherapy | EXPERIMENTAL | Participants will receive GTAEXS617 oral tablets in increasing doses. |
| Phase 1: Dose Escalation Combination Therapy | EXPERIMENTAL | Participants will receive GTAEXS617 oral tablets in increasing doses in combination with standard of care (SoC) treatment. |
| Phase 2: Dose Expansion Monotherapy | EXPERIMENTAL | Participants will receive GTAEXS617 oral tablets at Recommended Phase 2 Dose (RP2D). |
| Phase 2: Dose Expansion Combination Therapy | EXPERIMENTAL | Participants will receive GTAEXS617 oral tablets at RP2D in combination with SoC treatment. |
| Name | Type | Description |
|---|---|---|
| GTAEXS617 | DRUG | Administered as specified in the treatment arm. |
| SoC | DRUG | Participants will receive selected SoC regimen (fulvestrant, paclitaxel + bevacizumab, pegylated liposomal doxorubicin, or capecitabine) administered as specified in the treatment arm. |
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Life expectancy \> 3 months. * One of the following histologically or cytologically confirmed advanced solid tumors: head and neck squamous cell carcinoma (HNSCC), pancreatic adenocarcinoma, non-small cell...
GTAEXS617 is an investigational small molecule being studied for the treatment of advanced solid tumors, including Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, and Triple Negative Breast Cancer (TNBC).
GTAEXS617 is being developed by Recursion Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker RXRX.
GTAEXS617 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. It is currently being evaluated in a Phase 1 study for safety and tolerability in patients with advanced solid tumors.
GTAEXS617 is being studied in a single Phase 1 clinical trial, NCT05985655, titled "Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors." The trial is currently recruiting participants in the United States, Belgium, and the United Kingdom, with a planned enrollment of 230 patients.
The mechanism of action of GTAEXS617 has not been disclosed in the available information. It is a small molecule being investigated for its potential anti-tumor activity in multiple advanced solid tumor types.